You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 283 No. 5, February 2, 2000 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Editorial
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (2)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Long-term Outcomes and Management of Patients With Lyme Disease

Pierce Gardner, MD

JAMA. 2000;283:658-659.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Although Lyme disease was first recognized 25 years ago, serologic methods of diagnosis have not been well standardized, and there is significant variability between laboratories.1-3 In the absence of a criterion standard blood test, the diagnosis of Lyme disease is based on a characteristic clinical picture in the appropriate epidemiologic setting (often supported by serologic data). Because the initial IgM response to the causative spirochete Borrelia burgdorferi characteristically begins 1 to 2 weeks after infection, patients with early classic Lyme disease may be antibody-negative.4 Conversely, B burgdorferi expresses cross-reactive antigens and false-positive test results may occur, even using the recommended 2-step system of enzyme-linked immunosorbent assay (ELISA) screening (high sensitivity) followed by Western immunoblot (high specificity).5 To further complicate the issue, all the currently licensed ELISA tests contain the OspA surface antigen and, therefore, are invalid for individuals who have received the Lyme disease vaccine (composed of . . . [Full Text of this Article]

Author Affiliation: Department of Medicine, Infectious Disease Division, State University of New York at Stony Brook School of Medicine.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Long-term Outcomes of Persons With Lyme Disease
Elyse G. Seltzer, Michael A. Gerber, Matthew L. Cartter, Kimberly Freudigman, and Eugene D. Shapiro
JAMA. 2000;283(5):609-616.
ABSTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Benign Long-Term Outcomes for Lyme Disease Patients
JWatch Infect. Diseases 2000;2000:2-2.
FULL TEXT  

Chronic Refractory Lyme Disease Is Rare
JWatch Psychiatry 2000;2000:18-18.
FULL TEXT  

Chronic Refractory Lyme Disease Is Rare
JWatch General 2000;2000:2-2.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2000 American Medical Association. All Rights Reserved.